Fulcrum-Logo_Primary_Full-Color_RGB_Large copy.jpg
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023
February 27, 2024 07:00 ET | Fulcrum Therapeutics, Inc.
― On track to report topline data for Phase 3 REACH trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD) in the fourth quarter of 2024 ― ― Restart of the Phase 1b PIONEER trial of...
Fulcrum-Logo_Primary_Full-Color_RGB_Large copy.jpg
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on Tuesday, February 27, 2024, at 8:00 a.m. ET
February 20, 2024 16:01 ET | Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to...
Fulcrum-Logo_Primary_Full-Color_RGB_Large copy.jpg
Fulcrum Therapeutics to Participate at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 06, 2024 08:00 ET | Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., Feb. 06, 2024 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to...
Fulcrum-Logo_Primary_Full-Color_RGB_Large copy.jpg
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 07, 2023 16:30 ET | Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically...
Fulcrum-Logo_Primary_Full-Color_RGB_Large copy.jpg
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 10, 2023 16:30 ET | Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically...
Fulcrum-Logo_Primary_Full-Color_RGB_Large copy.jpg
Fulcrum Therapeutics to Participate at Upcoming November Investor Conferences
November 09, 2023 08:00 ET | Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to improve the lives...
Fulcrum-Logo_Primary_Full-Color_RGB_Large copy.jpg
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2023
November 07, 2023 07:00 ET | Fulcrum Therapeutics, Inc.
― Completed enrollment in the Phase 3 REACH trial of losmapimod in facioscapulohumeral muscular dystrophy (FSHD); expect to report topline data in the fourth quarter of 2024 ― ― U.S. Food and Drug...
Fulcrum-Logo_Primary_Full-Color_RGB_Large copy.jpg
Fulcrum Therapeutics to Host Third Quarter 2023 Financial Results Conference Call and Webcast on Tuesday, November 7, 2023, at 8:00 a.m. ET
October 31, 2023 08:50 ET | Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (the “Company”) (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on developing small molecules to...
Fulcrum-Logo_Primary_Full-Color_RGB_Large copy.jpg
Fulcrum Therapeutics to Participate at the Cantor Fitzgerald Global Healthcare Conference
September 22, 2023 08:00 ET | Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with...
Fulcrum-Logo_Primary_Full-Color_RGB_Large copy.jpg
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 15, 2023 16:30 ET | Fulcrum Therapeutics, Inc.
CAMBRIDGE, Mass., Sept. 15, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with...